Ecolab Inc. ECL has been gaining from its solid product portfolio. The optimism, led by a solid fourth-quarter 2025 performance and continued focus on research and development, is expected to contribute further. However, concerns regarding macroeconomic factors persist.
This Zacks Rank #3 (Hold) stock has gained 4.8% in the year-to-date period compared with the industry’s 11.9% growth. The S&P 500 Composite has decreased 0.5% during the same time frame.
The renowned water, hygiene and infection prevention solutions and services provider has a market capitalization of $77.2 billion. It projects 14.3% growth for the next five years and expects to maintain a strong performance in the future. Ecolab’s earnings surpassed the Zacks Consensus Estimate in two of the trailing four quarters, missed once and met once, delivering an average surprise of 0.23%.
Image Source: Zacks Investment Research
Reasons Favoring Ecolab’s Growth
Strong Product Portfolio With a Focus on R&D: On the fourth-quarter earnings call, management said Ecolab’s innovation pipeline remains strong, with increasing focus on digitally enabled solutions that boost customer productivity and sustainability. Platforms like 3D TRASAR and connected monitoring tools are gaining traction, helping customers optimize water, energy and operations while supporting premium pricing and deeper relationships. Management also highlighted the growing role of smart devices across customer sites, expecting deployments to exceed one million by 2026, enabling real-time monitoring, predictive insights and improved technician productivity.
Ecolab’s Global High-Tech Business & Digital Platform: On the fourth-quarter earnings call, management highlighted Ecolab’s Global High-Tech segment as a key long-term growth driver, supported by semiconductor and data-center investments, with double-digit growth in 2025. The planned Ovivo Electronics acquisition, expected in 2026, should expand ultrapure water capabilities and nearly double the High-Tech business to about $900 million.
Ecolab is also advancing liquid cooling solutions for AI data centers, including 3D TRASAR technologies that can cut cooling power use by up to 10%. Meanwhile, Ecolab Digital continues to scale, with 20% sales growth and annualized revenue above $400 million, representing a $13 billion opportunity driven by AI, remote monitoring and predictive analytics.
Strong Q4 Results: ECL exited the fourth quarter of 2025 with better-than-expected results. The company registered a robust year-over-year uptick in its top and bottom lines, along with solid performances across all segments. The expansion of both margins bodes well for the stock.
Per management, Ecolab’s performance in the reported quarter was led by accelerating organic sales growth across most businesses and significant operating income margin expansion. Management also confirmed that the company is driving better-than-expected savings from its One Ecolab productivity initiatives and now anticipates annualized savings to increase from $225 million to $325 million by 2027.
The recent acquisition of Ovivo Electronics ultrapure water business further strengthens Ecolab’s Global High-Tech business, creating an end-to-end water circularity offering for microelectronics customers and expanding the size of one of its most significant growth engines. This looked promising for the stock.
A Factor That May Offset ECL’s Gains
Macroeconomic Factors: Operating across 170 countries, Ecolab faces exposure to diverse social, political and economic risks. In its second-quarter earnings call, management highlighted ongoing macro headwinds, including tariff-driven inflation, with commodity costs rising in the low- to mid-single-digit range and likely to persist through the rest of the year.
The company also noted weaker demand in paper and basic industries, which have lagged more resilient segments, while unfavorable foreign exchange movements are expected to increase expenses compared to the last year.
Estimate Trend
Ecolab is witnessing a negative estimate revision trend for 2026. In the past 30 days, the Zacks Consensus Estimate for its earnings has moved south by 7 cents to $8.46 per share.
The Zacks Consensus Estimate for the company’s first-quarter 2026 revenues is pegged at $4.03 billion, indicating an 8.9% improvement from the year-ago quarter’s reported number.
Key Picks
Some better-ranked stocks from the broader medical space are Phibro Animal Health PAHC, GE HealthCare Technologies GEHC and Cardinal Health CAH.
Phibro Animal Health, currently sporting a Zacks Rank #1 (Strong Buy), reported second-quarter fiscal 2026 adjusted earnings per share (EPS) of 87 cents, which surpassed the Zacks Consensus Estimate by 27.1%. Revenues of $373.9 million beat the Zacks Consensus Estimate by 4.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 20.1%.
GE HealthCare Technologies, currently carrying a Zacks Rank #2 (Buy), reported fourth-quarter 2025 adjusted EPS of $1.44, which surpassed the Zacks Consensus Estimate by 0.7%. Revenues of $5.7 billion beat the Zacks Consensus Estimate by 1.9%.
GEHC has an estimated long-term earnings growth rate of 9.1% compared with the industry’s 12% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 7.5%.
Cardinal Health, currently carrying a Zacks Rank #2, reported a second-quarter fiscal 2026 adjusted EPS of $2.63, which surpassed the Zacks Consensus Estimate by 10%. Revenues of $65.6 billion beat the Zacks Consensus Estimate by 0.9%.
CAH has an estimated long-term earnings growth rate of 15% compared with the industry’s 9.3% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 9.3%.
Beyond Nvidia: AI's Second Wave Is Here
The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. Little-known AI firms tackling the world's biggest problems may be more lucrative in the coming months and years.
SeeWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Ecolab Inc. (ECL): Free Stock Analysis Report
Cardinal Health, Inc. (CAH): Free Stock Analysis Report
Phibro Animal Health Corporation (PAHC): Free Stock Analysis Report
GE HealthCare Technologies Inc. (GEHC): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).